What is the CoP network?
The CoP network will:
Offer structured training for young transplant professionals in HLA desensitisation
Promote multidisciplinary best practices in transplant care
Support collaborative research and innovation
Provide long-term leadership in the field of sensitised kidney transplantation
Objectives
We are excited to offer the following additional benefits as part of the CoP programme:
An ESOT Grant: €5,000, which can be allocated toward expenses for this project. The remaining funding should be used for ongoing research in kidney transplantation, publications in Transplant International, or travel grants to attend ESOT events.
Representation in an international scientific committee, including involvement with two experienced experts.
Opportunity for one young professional to participate in the programme and visit other Centres of Preceptorship.
Development and use of educational material, from which participants and centres alike will benefit.
How to Apply
Application Criteria
Opening: 1 August
Closing: 7 September
The CoP programme is a carefully structured educational experience offering:
This programme is designed to support not just clinical knowledge, but also to foster collaboration, innovation, and leadership in young professionals committed to improving transplant outcomes for sensitised patients.
Who can apply?
We welcome applications from young professionals who meet the following criteria:
Why this matters
The ESOT Centre of Preceptorship is a collective investment in the future of transplantation.
Through the CoP network, we are fostering a new model of cross-border training, multidisciplinary collaboration, and evidence-based innovation. Participants will not only benefit from local expertise, but also contribute to a Europe-wide dialogue on improving care for sensitised kidney recipients.
If you’re driven by a passion for transplantation and eager to grow in an inspiring environment, this programme is your next step.
How to Apply
Application Criteria
Opening: 1 September
Closing: 12 October
The project is possible thanks to the unrestricted grant from Hansa Biopharma.